Evotec SE (WBO:EVT) 3-Year Revenue Growth Rate : 12.60% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Evotec SE 3-Year Revenue Growth Rate?

Evotec SE's Revenue per Share for the three months ended in Dec. 2023 was €1.14.

During the past 12 months, Evotec SE's average Revenue per Share Growth Rate was 11.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 12.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 16.90% per year. During the past 10 years, the average Revenue per Share Growth Rate was 23.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Evotec SE was 40.00% per year. The lowest was -30.40% per year. And the median was 13.40% per year.

Competitive Comparison of Evotec SE's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evotec SE's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Evotec SE's 3-Year Revenue Growth Rate falls into.

Evotec SE 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Evotec SE (WBO:EVT) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Evotec SE 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Evotec SE's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Evotec SE (WBO:EVT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (WBO:EVT) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

EVO:USA EVOTF:USA 1EVT:Italy EVTd:UK 0IRF:UK EVT:Germany

Address

Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419

Website

https://www.evotec.com

Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.

Evotec SE (WBO:EVT) Headlines

From GuruFocus

Eaton Vance Tax-Advantaged Dividend Income Fund January 2021 Distribution

By PRNewswire PRNewswire • 01-15-2021

Unveiling the Dividend Performance of EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND (EVT)

By GuruFocus Research • 09-21-2023

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND's Dividend Analysis

By GuruFocus Research • 10-20-2023

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND's Dividend Analysis

By GuruFocus Research • 01-22-2024